62 articles
Asian stocks declined after a US tech selloff, while Rio Tinto suspended a copper mine and Eli Lilly raised its drug sales forecast. Oil prices wavered on geopolitical signals as investors rotated int
Eli Lilly shares hit a record high as obesity drug sales beat profit expectations and raised the full-year revenue forecast. Analysts remain optimistic about the company's dominance in the obesity and
Eli Lilly raised its full-year revenue forecast to $91-$92 billion driven by surging GLP-1 weight-loss drug sales, beating Q3 earnings expectations despite trimming profit guidance due to acquisition
A US judge denied Novo Nordisk's motion to block Eli Lilly's advertising for weight-loss drugs, finding claims of irreparable harm inadequate. The decision affects competition in the obesity drug mark
Hong Kong-listed Metis TechBio signed a collaboration agreement with Eli Lilly worth up to $1.1 billion for the R&D of tissue-specific drug delivery technologies.
The EMA recommended approval of Eli Lilly's oral weight-loss drug Foundayo, becoming the second such authorization after Novo Nordisk. Final EC approval is pending before launch in a market projected
Antares Therapeutics secured $177 million in Series A funding to develop small-molecule drugs targeting novel protein pockets, founded by former Scorpion Therapeutics executives after Eli Lilly acquir
Major pharmaceutical firms like Eli Lilly are advancing next-generation weight-loss molecules targeting GLP-1 and GIP receptors, building on current blockbusters like Zepbound and Mounjaro while seeki
The US FDA approved Eli Lilly's once-weekly basal insulin Onswik for type 2 diabetes, potentially reducing annual injections by over 300 compared to daily alternatives. Approval followed late-stage tr
Novo Nordisk announced its experimental drug CagriSema achieved 12.4% average weight loss in late-stage diabetes trials, outperforming Eli Lilly's tirzepatide at 9.1%. The combination therapy position
Novo Nordisk faces investor pressure to diversify beyond its blockbuster weight-loss drugs amid rising competition from Eli Lilly and impending semaglutide patent expiries. Analysts suggest acquisitio
Eli Lilly announced its oral obesity drug Foundayo captured over 30% of new US patients, narrowing the gap with rival Novo Nordisk. Market analysts expect the obesity treatment sector to reach over $1
Kura Oncology launched Caspian Therapeutics with $50 million to develop menin inhibitors for diabetes and cardiometabolic diseases. Backed by Eli Lilly and the T1D Fund, Kura retains a 50% stake in th
Novo Nordisk launched its oral Wegovy weight-loss pill in Germany following EU approval, intensifying competition with Eli Lilly in the expanding GLP-1 market. This semaglutide-based treatment targets
Novo Nordisk confirmed China's drug regulator accepted its application for an oral version of Wegovy, joining competitors like Eli Lilly in the expanding Chinese weight-loss market. Analysts project G
Major pharmaceutical companies employ indirect marketing to promote weight-loss drugs in China amidst strict regulations. Analysts project the GLP-1 therapy market could reach $4 billion within five t
Eli Lilly launched its oral weight-loss drug Foundayo (orforglipron) in the UK, marking the first European availability and offering a lower price point than injectable alternatives while pending EU r
Eli Lilly sued six companies for illegally selling unapproved black-market versions of its experimental obesity drug retatrutide, currently in Phase 3 trials. Highlighting safety risks, the firm urged
Britain's MHRA approved Eli Lilly's oral weight-loss pill Foundayo for diabetes and weight management, marking the first European authorization. The drug launches privately later this month, intensify
Major oil companies reported record refining profits driven by tight global supply, while pharmaceutical leaders Eli Lilly and Merck contributed to a strong quarterly earnings season amidst geopolitic
Asian stocks declined as AI momentum faded, influenced by geopolitical hopes easing oil prices. Eli Lilly raised sales guidance on weight-loss drugs, contrasting with broader market caution.
Eli Lilly raised its full-year revenue forecast following better-than-expected quarterly results driven by GLP-1 drug sales Mounjaro and Zepbound. Shares surged 5% amid resilient demand despite pricin
US markets hit record highs on earnings and falling oil prices, despite Red Sea shipping risks. Key updates include SpaceX earnings and upcoming reports from Eli Lilly and AMD.
Eli Lilly announced an expanded access program for its experimental obesity drug retatrutide prior to FDA approval for specific severe cases. The company plans to file for approval in Q1 next year fol
Novo Nordisk shares climbed 35% as its oral Wegovy competes strongly against Eli Lilly's Zepbound in the projected $100 billion obesity market. Investors await Q2 results to assess the durability of t
Eli Lilly and Resilience plan to invest $750 million to expand U.S. pharmaceutical manufacturing capacity, strengthening the domestic medicine supply chain and creating 400 jobs. The partnership will
Novo Nordisk sued Eli Lilly over allegedly misleading advertising for their weight-loss drugs, claiming the rival used outdated studies to imply superiority. Eli Lilly defended its campaign, citing di
Novo Nordisk sued Eli Lilly in U.S. court, alleging false advertising claims comparing their weight-loss drugs Zepbound and Wegovy. The lawsuit underscores fierce competition in the obesity market, re
Asian stocks are poised to decline following a US chipmaker selloff, while crude oil prices rose amid Middle East tensions. Pharmaceutical leaders Merck and Eli Lilly announced regulatory approvals an
US premarket trading saw mixed results amid geopolitical tensions and corporate earnings. Notable movements included an oil tanker strike impacting energy sectors and Eli Lilly exploring an acquisitio
ChemBrief